V1RD22 Inhibitors
V1RD22 inhibitors encompass a range of chemical compounds that target specific signaling pathways to achieve inhibition of the protein's functional activity. LY294002 and Wortmannin, as potent PI3K inhibitors, block the PI3K/AKT signaling pathway crucial for the activity of many proteins, including V1RD22. By preventing activation through this pathway, these inhibitors can effectively decrease V1RD22 function. Similarly, PD98059 and U0126 are selective for the MEK1/2 enzymes and by disrupting the ERK/MAPK signaling, they too contribute to the indirect inhibition of V1RD22. Compounds like SB203580 and SP600125, which target the p38 MAPK and JNK signaling pathways respectively, demonstrate how the inhibition of these specific pathways can potentially impact V1RD22's activity, provided it is a downstream effector. Bortezomib's proteasome inhibition might also alter the degradation patterns of proteins that regulate V1RD22, thereby affecting its activity.
Further extending the arsenal of V1RD22 inhibitorsare Sunitinib and Dasatinib, which function as receptor tyrosine kinase inhibitors, and thereby have the potential to alter the activity of V1RD22 by affecting the signaling pathways it is involved in. Sunitinib targets multiple RTKs, which could impact V1RD22 if it is regulated by these kinases. Dasatinib, by inhibiting Src-family kinases, could similarly reduce V1RD22 activity by influencing relevant downstream signaling. Triciribine and Rapamycin focus on the AKT and mTOR pathways, respectively, offering additional routes to dampen V1RD22 signaling by inhibiting key nodes that might influence its activity. Lastly, Gefitinib inhibits EGFR tyrosine kinase, another possible upstream regulator of V1RD22, adding yet another layer of indirect inhibition through interference with growth factor signaling. Collectively, these inhibitors demonstrate the multifaceted approach to modulating V1RD22 activity by targeting various signaling cascades that contribute to its functional state.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 blocks the PI3K/AKT signaling pathway. This leads to the inhibition of downstream targets, including V1RD22, by preventing its activation through this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK1, PD98059 prevents the activation of MEK1 and subsequently inhibits the ERK/MAPK signaling pathway. This results in indirect inhibition of V1RD22, which is modulated through this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Specifically inhibits the p38 MAPK pathway by targeting p38α and p38β. By blocking this pathway, SB203580 can indirectly inhibit V1RD22 activity if V1RD22 is a downstream effector of the p38 MAPK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
As an inhibitor of MEK1 and MEK2, U0126 interferes with the activation of MAPK/ERK kinase, thereby indirectly inhibiting V1RD22 if V1RD22's function is regulated via the ERK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that binds to FKBP12 and blocks the activation of mTORC1. This inhibition can decrease the activity of V1RD22 if it is downstream or regulated by the mTOR signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another potent PI3K inhibitor, wortmannin covalently binds to and inhibits PI3K, leading to the inhibition of the PI3K/AKT pathway and potentially reducing V1RD22 activity if it relies on this signaling for its activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits the JNK signaling pathway by binding to and inhibiting JNK1, JNK2, and JNK3. Indirect inhibition of V1RD22 may occur if it is functionally associated with the JNK pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can lead to the accumulation of regulatory proteins that are normally degraded, potentially altering the signaling pathways that V1RD22 is involved in and inhibiting its activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
A receptor tyrosine kinase inhibitor that targets multiple RTKs, which could indirectly affect the signaling pathways controlling V1RD22 activity, particularly if V1RD22 is involved in pathways regulated by these RTKs. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A Src-family tyrosine kinase inhibitor that could potentially inhibit V1RD22 by interfering with downstream signaling pathways that involve Src kinases, assuming V1RD22 is regulated by such pathways. | ||||||